MétaCan
Menu
Back to cohort
Record W4379416154 · doi:10.1353/bhm.2010.a408232

The Convergence of Science and Governance: Research, Health Policy, and American States (review)

2010· article· en· W4379416154 on OpenAlexaboutno aff
Daniel Carpenter

Bibliographic record

VenueBulletin of the history of medicine · 2010
Typearticle
Languageen
FieldPharmacology, Toxicology and Pharmaceutics
TopicPharmaceutical industry and healthcare
Canadian institutionsnot available
Fundersnot available
KeywordsMedicaidCorporate governancePublic administrationState (computer science)Political scienceHealth careLegislationConvergence (economics)Health policyLawManagementEconomic growthEconomics

Abstract

fetched live from OpenAlex

Reviewed by: The Convergence of Science and Governance: Research, Health Policy, and American States Daniel Carpenter Daniel M. Fox . The Convergence of Science and Governance: Research, Health Policy, and American States. Berkeley: University of California Press, 2010. xii + 168 pp. $29.95 (978-0-520-26238-6). In the aftermath of congressional passage of federal legislation that will shape American health care for decades to come, it is easy to forget that significant and monumental health reform has been shaped by state governments. Daniel Fox's Convergence of Science and Governance documents a gradual but substantial transformation in the way that states regulate and compensate health services. In Fox's lovely and concise volume, the states effect broad shifts in methods, rules, concepts, and resource allocation. These shifts portend and presage much of what can be expected to occupy the agendas and minds of policy makers in state capitols and Washington in the coming decades. Fox conveys how state health policy makers have come to regulate therapeutics and health services by relying on systematic reviews of comparative treatment effectiveness. Some of the names and networks in this narrative are familiar—in particular Donald Berwick, who at this writing has been nominated by President Obama for head of the Centers for Medicare & Medicaid Services. Yet Fox introduces us to new personalities in this saga. They range from female effectiveness pioneer Mindel C. Sheps and University of Michigan scholar Avedis Donabedian to Oregon officials Mark Gibson and Mark Helfand to policy makers in Idaho, Washington, and Canadian provinces who became early and risk-taking champions of coverage policy based on systematic evidentiary reviews. There are also previously understudied networks and organizations that will now, thanks to Fox, populate the annals of health service reform: the Reforming States Group, the founders of the Drug Effectiveness Research Project (pp. 80-82) in the western states, the federal government's User Liaison Program. [End Page 706] In a volume that functions as an intersection of political and methodological history—I am reminded, in some ways, of Richard White's brief and boundary-spanning Organic Machine—Fox gives shrewd attention to the political economy of health research methods. He ably shows how randomized trials have transformed many debates but also how their prohibitive cost tends to confer advantages on the organizations that can afford to sponsor them (pp. 7, 22). The modern embrace of randomized controlled trial methods leads to a cat-and-mouse game about how to perform these studies and how to apply their lessons (see his concluding chap. 5). And Fox exhibits a sharp understanding of the role, limitations, and complicated politics of statistical inference. His musings about the tension between average effects and individual or subpopulation results and his cautionary notes about libertarian and industry-sponsored abuses of the distinction should be required reading in graduate seminars (pp. 92-93). Fox devotes chapter 4 to an understanding of the Drug Effectiveness Review Project (DERP). It is, in my reading, the crowning effort of the book and represents simply the best encapsulation and narrative on the project that has been written. The fledgling effort received a political boost from its narrow passage in Oregon and the failure of a judicial challenge to Maine's law, and the role of DERP systems in sounding an early warning on Vioxx and its cardiovascular risks lent additional legitimacy to the effort. There is convergence is this narrative, but Fox avoids teleology. There are limitations to an effort like this, not least a somewhat contrived distinction between "general government" and "specialist government." This binary both confuses the reader and results in what, for a gifted historical writer, are some rather anachronistic statements (the idea that state government specialists' "priority is to justify, and advocate for, more money and authority for their agencies"; p. 52). Yet the credits far outpace the debits here. The deep legacy of American health reform in the twenty-first century expresses and signifies, perhaps inescapably, a deeply federalist history. More than any scholar writing, Daniel Fox has set readers on that path of understanding. Daniel Carpenter Harvard University Copyright © 2010 The Johns Hopkins University Press

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.020
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesScience and technology studies
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.999
Threshold uncertainty score0.032

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.020
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0030.002
Bibliometrics0.0080.012
Science and technology studies0.0010.001
Scholarly communication0.0060.005
Open science0.0010.002
Research integrity0.0030.004
Insufficient payload (model declined to judge)0.0090.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.312
GPT teacher head0.555
Teacher spread0.243 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2010
Admission routes1
Has abstractyes

Explore more

Same venueBulletin of the history of medicineSame topicPharmaceutical industry and healthcareFrench-language works237,207